Every 10-Q that TRULIEVE CANNABIS CORP (TCNNF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TCNNF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCNNF filings page.
Trulieve Cannabis Corp. reoriented its structure in the first half of 2026 by completing a Deconsolidation Transaction on June 3, 2026, in which mixed-use cannabis subsidiary Harvest was deconsolidated and retained as a 90% equity method investment. This triggered a largely non‑cash loss of $403.333 million and drove a Q2 net loss of $406.062 million, compared with a small loss a year earlier. Q2 2026 revenue declined about 10% to $270.952 million, though gross margin remained near 60%.
After the transaction Trulieve operates exclusively in medical cannabis markets across four states, with 206 dispensaries and 10 cultivation/processing sites, and holds a $152.503 million equity method stake in Harvest plus a management services agreement generating fee revenue. Cash and cash equivalents increased to $325.420 million as of June 30, 2026, supported by $108.847 million of operating cash flow in the first six months, while long‑term funding includes $200.000 million of 10.50% 2030 private placement notes and $94.551 million of other notes payable. Federal rescheduling of medical cannabis to Schedule III led the company to compute 2026 taxes without applying IRC Section 280E to medical operations, lowering its effective tax rate even as legacy uncertain tax position liabilities remain high at $598.187 million.
Trulieve Cannabis Corp. reported mixed Q1 2026 results. Revenue was $286.8 million, down about 4% year over year as retail sales declined on price compression, partly offset by stronger wholesale revenue. Gross margin slipped to 59.3% from 61.5%.
The company generated net income of $2.3 million versus a $33.8 million loss a year earlier, helped by sharply lower campaign and political spending and a smaller tax provision. Adjusted EBITDA was $100.4 million, or 35.0% of revenue. Cash and cash equivalents rose to $352.9 million, supported by $55.7 million of operating cash flow and new private placement debt. Management highlighted the U.S. decision to reschedule medical cannabis to Schedule III and its applications for DEA licenses in key medical markets as a structural shift in its tax and regulatory profile.
Trulieve Cannabis Corp. filed its Q3 2025 report, posting revenue of $288.2 million and a net loss of $28.8 million. Gross margin was 58.9%, and SG&A fell sharply as political contributions declined year over year. Despite positive operating income, a high tax provision drove bottom-line losses.
Liquidity remained strong with cash and cash equivalents of $449.2 million at quarter end. Year-to-date, operating cash flow was $213.6 million, and Adjusted EBITDA reached $102.7 million in Q3. Uncertain tax position liabilities were $616.3 million, reflecting ongoing tax disputes disclosed by the company. Subsequent event: Trulieve issued a notice of redemption for all outstanding 8% 2026 Notes, totaling $368.0 million, at par plus accrued interest, with a scheduled redemption date of December 5, 2025.